

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-12. Cancelled.

Claims 13-21. Cancelled.

Claim 22. Cancelled.

Claim 23. Cancelled.

Claim 24. Cancelled.

Claim 25. Cancelled.

Claims 26-28. Cancelled.

Claim 29. (Previously added) A method for enhancing an immune response in a patient, comprising:

- (a) administering to the patient a composition comprising an isolated polypeptide, wherein the polypeptide comprises SEQ ID NO: 33; and
- (b) enhancing an immune response in the patient.

Claim 30. (Previously added) The method of claim 29, wherein the composition further comprises at least one component selected from the group consisting of: physiologically acceptable carriers and non-specific immune response enhancers.

Claim 31. (Previously added) A method for enhancing an immune response in a patient, comprising:

- (a) administering to the patient a composition comprising an isolated polypeptide, wherein the polypeptide comprises a sequence selected from the group consisting of sequences having at least 95% identity to SEQ ID NO: 33 and wherein the polypeptide has the same functional properties as SEQ ID NO: 33; and
- (b) enhancing an immune response in the patient.

Claim 32. (Previously added) The method of claim 31, wherein the composition further comprises at least one component selected from the group consisting of: physiologically acceptable carriers and non-specific immune response enhancers.

Claim 33. Cancelled.

Claim 34. Cancelled.

Claim 35. Cancelled.

Claim 36. Cancelled.

Claim 37. (Previously added) A method for enhancing an immune response in a patient, comprising:

- (a) administering to the patient a composition comprising an isolated polypeptide, wherein the polypeptide comprises a sequence selected from the group consisting of sequences having at least 95% identity to SEQ ID NO: 33 and is able to bind to fibroblast growth factor; and
- (b) enhancing an immune response in the patient.

Claim 38. (Previously added) The method of claim 37, wherein the composition further comprises at least one component selected from the group consisting of: physiologically acceptable carriers and non-specific immune response enhancers.

Claim 39. (New) The method of claim 29, wherein the composition is administered by injection.

Claim 40. (New) The method of claim 30, wherein the physiologically acceptable carrier is selected from the group consisting of: water, saline, alcohol, lipids, waxes, buffers, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, magnesium carbonate and biodegradable microspheres.

Claim 41. (New) The method of claim 30, wherein the non-specific immune response enhancer is an adjuvant.

Claim 42. (New) The method of claim 31, wherein the composition is administered by injection.

Claim 43. (New) The method of claim 32, wherein the physiologically acceptable carrier is selected from the group consisting of: water, saline, alcohol, lipids, waxes, buffers, mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, magnesium carbonate and biodegradable microspheres.

Claim 44. (New) The method of claim 32, wherein the non-specific immune response enhancer is an adjuvant.

Claim 45. (New) The method of claim 37, wherein the composition is administered by injection.

Claim 46. (New) The method of claim 38, wherein the physiologically acceptable carrier is selected from the group consisting of: water, saline, alcohol, lipids, waxes, buffers, mannitol,

1.
1.
lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, magnesium carbonate and biodegradable microspheres.

Claim 47. (New) The method of claim 38, wherein the non-specific immune response enhancer is an adjuvant.
